🔗 Share this article

An underground market for unapproved slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Experimental Treatment Gaining Popularity Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its supposed fat-burning properties. Followers are encouraged to message these accounts directly for supplier links, while also obtaining promotional offers.

Active Commerce on Social Networks

Separately, a robust trade exists on Telegram, where communities with thousands of participants share “before and after” photos, administration instructions and claims of next-day British shipping. Vendors market the substance there before directing buyers to WhatsApp for transactions.

Learning About Retatrutide

Retatrutide is an investigational injection developed by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.

Healthcare Professionals Voice Worries

However, doctors and pharmacists have cautions that the distribution of what is still an unapproved medication in the UK is worrisome and could result in individuals administering substances of unknown origin.

Some experts said the popularity for retatrutide could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Regulatory Status and Enforcement

Selling retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the British medical regulations.

Several influencers try to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still breach medicines, marketing, and customer laws, potentially leading to fines, prosecution or prison.

Platform Response and Content Removal

Based on TikTok, the platform has removed problematic content and prohibited related hashtags and search suggestions. The company stated it was dedicated to keeping the platform safe and allocating resources in enhancing compliance measures.

Online Trading Operations

Investigations also found groups with up to nine thousand participants marketing the experimental drug using the platform's integrated search feature, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of users, populated with photos of weight loss, positive testimonials and step-by-step instructions for mixing or injecting at home.

Within moments of joining one community, a vendor shared WhatsApp details, where the majority of purchases occur. The seller sent an instruction manual and guaranteed delivery within 48 hours. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None inquired about weight, medical conditions or past usage.

Item Information and Costs

Inside these groups, posts show black plastic packages with postal service stickers, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at home with sterile water, or ready-to-use pens typically sold at 160 pounds for 20 milligrams. When questioned how much time a injector should last, vendors give conflicting responses ranging from a few weeks to “depends on your body”.

Platform Moderation and Safety Measures

A spokesperson for Telegram said it regularly monitored dangerous material on its platform including material that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering substances they can’t verify. Although the research behind retatrutide is sound, these digital versions may not include what they advertise,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor connected the increase in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With costs rising, patients are using social media. But fake injections are extremely risky. You can’t be certain what’s inside or whether the environment they were made in was sterile,” she explained.

Her team has previously seen patients injured by personal administration from unverified suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Manufacturer Statement

A representative from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can market [it] for human use,” they said, adding that any item “falsely representing itself as a Lilly experimental product not yet approved … may expose users to possibly significant health risks”.